177 related articles for article (PubMed ID: 27545060)
1. [OMALIZUMAB RESCUED A ASTHMA-COPD OVERLAP SYNDROME PATIENT FROM A STATUS ASTHMATICS UNDER THE ICU MANAGEMENT].
Gamo S; Iijima H; Seki Y; Horaguchi R; Suda Y; Shindoh Y
Arerugi; 2016 Jul; 65(7):937-41. PubMed ID: 27545060
[TBL] [Abstract][Full Text] [Related]
2. Should omalizumab be used in severe asthma/COPD overlap?
Sposato B; Scalese M; Milanese M; Masieri S; Cavaliere C; Ricci A; Paggiaro P
J Biol Regul Homeost Agents; 2018; 32(4):755-761. PubMed ID: 30043557
[TBL] [Abstract][Full Text] [Related]
3. Omalizumab effectiveness in asthma-COPD overlap: Post hoc analysis of PROSPERO.
Hanania NA; Chipps BE; Griffin NM; Yoo B; Iqbal A; Casale TB
J Allergy Clin Immunol; 2019 Apr; 143(4):1629-1633.e2. PubMed ID: 30576755
[No Abstract] [Full Text] [Related]
4. Challenges in the management of asthma associated with smoking-induced airway diseases.
Thomson NC
Expert Opin Pharmacother; 2018 Oct; 19(14):1565-1579. PubMed ID: 30196731
[TBL] [Abstract][Full Text] [Related]
5. Omalizumab treatment in asthma-COPD overlap syndrome.
Tat TS; Cilli A
J Asthma; 2016 Dec; 53(10):1048-50. PubMed ID: 27144514
[TBL] [Abstract][Full Text] [Related]
6. Treatment responsiveness of phenotypes of symptomatic airways obstruction in adults.
Fingleton J; Travers J; Williams M; Charles T; Bowles D; Strik R; Shirtcliffe P; Weatherall M; Beasley R;
J Allergy Clin Immunol; 2015 Sep; 136(3):601-9. PubMed ID: 25746966
[TBL] [Abstract][Full Text] [Related]
7. Therapeutic approaches to asthma-chronic obstructive pulmonary disease overlap syndromes.
Barnes PJ
J Allergy Clin Immunol; 2015 Sep; 136(3):531-45. PubMed ID: 26343937
[TBL] [Abstract][Full Text] [Related]
8. Pediatric severe asthma: a case series report and perspectives on anti-IgE treatment.
Mirra V; Montella S; Santamaria F
BMC Pediatr; 2018 Feb; 18(1):73. PubMed ID: 29466963
[TBL] [Abstract][Full Text] [Related]
9. Can Xolair Be Used in Nonallergic Asthmatic?
Ledford DK; Casale TB
J Allergy Clin Immunol Pract; 2018; 6(6):2170. PubMed ID: 30390909
[No Abstract] [Full Text] [Related]
10. [Severe uncontrolled asthma in patients over 75 years old: Treatment with omalizumab].
Romand P; Kelkel E; Saint-Raymond C; Glas N; Caillaud D; Devouassoux G
Rev Mal Respir; 2016 May; 33(5):397-400. PubMed ID: 26346416
[TBL] [Abstract][Full Text] [Related]
11. Omalizumab therapy in a 13-year-old boy with severe persistent asthma and concomitant eosinophilic esophagitis.
Arasi S; Costa S; Magazzù G; Ieni A; Crisafulli G; Caminiti L; Chiera F; Vaccaro M; Del Giudice MM; Pajno GB
Ital J Pediatr; 2016 Mar; 42():32. PubMed ID: 27000314
[TBL] [Abstract][Full Text] [Related]
12. A review of omalizumab for the management of severe asthma.
Lin CH; Cheng SL
Drug Des Devel Ther; 2016; 10():2369-78. PubMed ID: 27528798
[TBL] [Abstract][Full Text] [Related]
13. Asthma control in severe asthmatics under treatment with omalizumab: a cross-sectional observational study in Italy.
Novelli F; Latorre M; Vergura L; Caiaffa MF; Camiciottoli G; Guarnieri G; Matucci A; Macchia L; Vianello A; Vultaggio A; Celi A; Cazzola M; Paggiaro P;
Pulm Pharmacol Ther; 2015 Apr; 31():123-9. PubMed ID: 25281265
[TBL] [Abstract][Full Text] [Related]
14. [The add-on effect of omalizumab on patients with uncontrolled bronchial asthma].
Minami Y; Endo S; Okumur S; Sasaki T; Yamamoto Y; Ogasa T; Osanai S; Ohsaki Y
Nihon Kokyuki Gakkai Zasshi; 2011 Nov; 49(11):793-9. PubMed ID: 22171481
[TBL] [Abstract][Full Text] [Related]
15. Omalizumab (anti-IgE) therapy in the asthma-COPD overlap syndrome (ACOS) and its effects on circulating cytokine levels.
Yalcin AD; Celik B; Yalcin AN
Immunopharmacol Immunotoxicol; 2016 Jun; 38(3):253-6. PubMed ID: 27121601
[TBL] [Abstract][Full Text] [Related]
16. Autoimmune polyendocrine syndrome type 2 in patient with severe allergic asthma treated with omalizumab.
Rams A; Żółciński M; Zastrzeżyńska W; Polański S; Serafin A; Wilańska J; Musiał J; Bazan-Socha S
J Asthma; 2018 Dec; 55(12):1384-1386. PubMed ID: 29300536
[TBL] [Abstract][Full Text] [Related]
17. Omalizumab and allergen immunotherapy in a patient with asthma and inhaled corticosteroid-induced adrenal suppression.
Forbush JT; Banks TA
Ann Allergy Asthma Immunol; 2016 Sep; 117(3):335-7. PubMed ID: 27613470
[No Abstract] [Full Text] [Related]
18. A comparison of the efficacy of once-daily fluticasone furoate/vilanterole with twice-daily fluticasone propionate/salmeterol in asthma-COPD overlap syndrome.
Ishiura Y; Fujimura M; Shiba Y; Ohkura N; Hara J; Kasahara K
Pulm Pharmacol Ther; 2015 Dec; 35():28-33. PubMed ID: 26497109
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and safety of a recombinant anti-immunoglobulin E antibody (omalizumab) in severe allergic asthma.
Holgate ST; Chuchalin AG; Hébert J; Lötvall J; Persson GB; Chung KF; Bousquet J; Kerstjens HA; Fox H; Thirlwell J; Cioppa GD;
Clin Exp Allergy; 2004 Apr; 34(4):632-8. PubMed ID: 15080818
[TBL] [Abstract][Full Text] [Related]
20. Omalizumab Is Equally Effective in Persistent Allergic Oral Corticosteroid-Dependent Asthma Caused by Either Seasonal or Perennial Allergens: A Pilot Study.
Domingo C; Pomares X; Navarro A; Rudi N; Sogo A; Dávila I; Mirapeix RM
Int J Mol Sci; 2017 Feb; 18(3):. PubMed ID: 28264494
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
